Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) - Medical equipment maker Thermo Fisher Scientific Inc on Wednesday forecast annual profit below Wall Street estimates, as it expects that a slump in demand for its services used to make therapeutics and vaccines to continue this year.
The company forecast an adjusted profit between $20.95 and $22.00 per share for 2024.
Analysts on average were expecting a profit of $22.04 per share in the year, according to LSEG data.
Thermo Fisher and rival Danaher have seen sluggish demand throughout last year for their bioprocessing services used to make therapies and vaccines, as their biotech clients were cautious in their drug development spending owing to rising interest rates.
Slowing growth in China, a key market for both the companies, has also crimped demand for contract research services and lab equipment.
Thermo said it expects revenue of $42.1 billion to $43.3 billion this year, below analysts' expectations of $42.93 billion.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
